- Home
- MDWD vs SANG Comparison
MDWD vs SANG Comparison
Compare MDWD & SANG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MDWD
- SANG
- Stock Information
- Founded
- MDWD 2000
- SANG 1984
- Country
- MDWD Israel
- SANG Canada
- Employees
- MDWD N/A
- SANG N/A
- Industry
- MDWD Medicinal Chemicals and Botanical Products
- SANG Computer Software: Programming Data Processing
- Sector
- MDWD Health Care
- SANG Technology
- Exchange
- MDWD Nasdaq
- SANG Nasdaq
- Market Cap
- MDWD 184.8M
- SANG 235.6M
- IPO Year
- MDWD 2014
- SANG 2021
- Fundamental
- Price
- MDWD $19.02
- SANG $7.01
- Analyst Decision
- MDWD Strong Buy
- SANG
- Analyst Count
- MDWD 1
- SANG 0
- Target Price
- MDWD $25.00
- SANG N/A
- AVG Volume (30 Days)
- MDWD 61.7K
- SANG 7.6K
- Earning Date
- MDWD 11-26-2024
- SANG 02-06-2025
- Dividend Yield
- MDWD N/A
- SANG N/A
- EPS Growth
- MDWD N/A
- SANG N/A
- EPS
- MDWD N/A
- SANG N/A
- Revenue
- MDWD $19,720,000.00
- SANG $244,406,000.00
- Revenue This Year
- MDWD $10.37
- SANG $3.36
- Revenue Next Year
- MDWD $26.36
- SANG $7.39
- P/E Ratio
- MDWD N/A
- SANG N/A
- Revenue Growth
- MDWD N/A
- SANG N/A
- 52 Week Low
- MDWD $11.04
- SANG $2.50
- 52 Week High
- MDWD $24.00
- SANG $7.20
- Technical
- Relative Strength Index (RSI)
- MDWD 61.79
- SANG 57.08
- Support Level
- MDWD $15.80
- SANG $6.89
- Resistance Level
- MDWD $18.25
- SANG $7.15
- Average True Range (ATR)
- MDWD 0.88
- SANG 0.20
- MACD
- MDWD 0.07
- SANG -0.02
- Stochastic Oscillator
- MDWD 95.27
- SANG 51.28
About MDWD MediWound Ltd.
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.
About SANG Sangoma Technologies Corporation
Sangoma Technologies Corp is a provider of hardware and software components that enable or enhance Internet Protocol Communications Systems for both telecom and datacom applications. It is engaged in the development, manufacturing, distribution, and support of voice and data connectivity components for software-based communication applications. Its product includes data and telecom boards for media and signal processing, as well as gateway appliances and software. The Company sells into two geographic centers: USA and Other countries. Key revenue is generated from USA.